BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 9676215)

  • 1. [Cost analysis of ultrasound-guided transrectal needle biopsy in prostatic carcinoma].
    Bissoli E; Fandella A; La Torre E; Faggiano L; Anselmo G; Frasson F
    Radiol Med; 1998 Apr; 95(4):353-6. PubMed ID: 9676215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of costs of transrectal prostate biopsy.
    Fandella A
    Urologia; 2011; 78(4):288-92. PubMed ID: 22139803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
    Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C
    Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
    Akduman B; Alkibay T; Tuncel A; Bozkirli I
    Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
    Shao Q; Song J; Zhou ZJ; Du LD
    Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A long follow-up on prostate specific antigen density and prostate biopsy.
    Netto Júnior NR; De Lima ML; Lavoura Júnior Nda S; Apuzzo F; De Lucena RG
    Arch Esp Urol; 1998 Dec; 51(10):1050-3. PubMed ID: 9951132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
    Men S; Cakar B; Conkbayir I; Hekimoglu B
    J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The usefulness of percentage of free prostate specific antigen/prostate specific antigen density in the diagnosis of prostate cancer].
    Han G; Gao JP; Cao XL; Hong BF; Tang J
    Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):379-81. PubMed ID: 16638346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men.
    Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M
    Urol J; 2009; 6(3):182-8. PubMed ID: 19711272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
    Rahardjo D; Kamil ST; Pakasi LS
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer detection with digital rectal examination, prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice.
    Ng TK; Vasilareas D; Mitterdorfer AJ; Maher PO; Lalak A
    BJU Int; 2005 Mar; 95(4):545-8. PubMed ID: 15705077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
    Chiang IN; Chang SJ; Pu YS; Huang KH; Yu HJ; Huang CY
    Urol Int; 2009; 82(3):270-5. PubMed ID: 19440012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of free and total prostate specific antigen in identifying patients for prostatic biopsy and its relationship to Gleason score and number of positive cores.
    Bulbul MA; Khauli RB; Nasr R; Hemady K; Wazzan W
    J Med Liban; 2000; 48(2):59-62. PubMed ID: 11028151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy.
    Miyakubo M; Ito K; Yamamoto T; Takechi H; Ohi M; Suzuki K
    Int J Urol; 2009 Jun; 16(6):561-5. PubMed ID: 19456991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer.
    Mitchell ID; Croal BL; Dickie A; Cohen NP; Ross I
    J Urol; 2001 May; 165(5):1549-53. PubMed ID: 11342915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer].
    Iwaki H; Kajita Y; Shimizu Y; Yamauchi T
    Hinyokika Kiyo; 2001 Mar; 47(3):169-74. PubMed ID: 11329957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection.
    Naughton CK; Miller DC; Mager DE; Ornstein DK; Catalona WJ
    J Urol; 2000 Aug; 164(2):388-92. PubMed ID: 10893592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
    Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
    Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.